Are the generic drugs of lenvatinib/lenvatinib as effective as the original drug? How to choose

Lenvatinib/Lenvatinib (Lenvatinib), as a multi-target tyrosine kinase inhibitor, has been widely used in the treatment of a variety of advanced solid tumors since the launch of the original brand, especially in the combination therapy of differentiated thyroid cancer, renal cancer, liver cancer and endometrial cancer. It has shown an important role. As its patent period comes to an end, generic versions have appeared in some countries or regions, and patients and clinicians are beginning to face the problem of choosing between original drugs or generic drugs. In medical practice, the core of a generic drug is whether it has the same efficacy and safety as the original drug.

From a regulatory perspective, generic drugs must undergo strict bioequivalence evaluation before obtaining marketing authorization, that is, they must prove that their absorption rate and extent in the human body are highly consistent with that of the original drugs. Internationally, FDA, EMA, and China's State Food and Drug Administration have all formulated clear equivalence standards, which means that generic drugs can theoretically achieve similar therapeutic effects to original drugs on the premise that the pharmacokinetics and main ingredients are consistent. However, lenvatinib is a targeted therapy drug that is highly dependent on precise dosage control. During the treatment process, the dosage needs to be adjusted frequently to deal with individual differences and adverse drug reactions, which places higher requirements on the production quality control of generic drugs.

In some clinical practices, doctors are more likely to give priority to recommending original drugs, especially among patients with complex conditions or who require combination immunotherapy. This is mainly due to higher trust in the stability and consistency of original drugs. However, in situations of heavy financial burden, medical insurance restrictions or long-term medication scenarios, compliantly produced generic drugs can undoubtedly provide a more cost-effective option. For patients who choose generic drugs, they should ensure that the drugs are produced with national approval and pass bioequivalence verification, and should be followed up regularly to monitor treatment response and side effects.

Reference materials:https://www.lenvima.com/